The Episode You've Been Waiting For Your Whole Life

Hidradenitis suppurativa (HS) management requires early, aggressive intervention to prevent irreversible scarring and tunneling, shifting the focus toward a "window of opportunity" for biologic therapy. Dr. Chris Sayed, an HS expert, joins the panel to analyze recent clinical data, including two-year results for bimekizumab, which demonstrate significant reduction in inflammatory nodules and draining tunnels. While biologics remain a cornerstone of treatment, surgical de-roofing and targeted antibiotic rescue therapies like ertapenem and linezolid provide essential support for managing acute flares and stabilizing disease progression. Despite the challenges of insurance authorization and potential cytokine shifts, early initiation of systemic therapy and proactive surgical management significantly improve long-term patient outcomes. Dermatologists must act as primary coordinators for these complex cases to ensure patients avoid the long-term physical and psychological burdens of advanced HS.